Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Pirlindole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.85 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.85 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.85 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.85 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.85 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.85 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.85 |
| ▸ | MAOA | P21397 | 1/20 | 0.85 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirlindole SCHEMBL30984462 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL18878061 | 0.92 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL373564 | 0.92 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL29500947 | 0.92 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL18877133 | 0.92 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL4157397 | 0.91 | HSD17B10 (0.97) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL1649683 | 0.90 | HSD17B10 (0.95) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL4152460 | 0.86 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL16418121 | 0.83 | HSD17B10 (0.71) | HSD17B10CYP1A2CYP2D6MEN1KMT2A | |
| Pirlindole SCHEMBL17241165 | 0.80 | HSD17B10 (0.68) | HSD17B10CYP1A2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BIOPHAGY INC (US) | 2022-03-10 | — | — | US | claimed |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | claimed |
| EP-3918056-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | Stemonix Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| US-20200400651-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | AXOSIM, INC. | 2020-12-24 | — | — | US | claimed |
| US-10736910-B2 | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits | STC.UNM (US) | 2020-08-11 | — | — | US | claimed |
| WO-2020160470-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | StemoniX Inc. (US) | 2020-08-06 | — | — | WO | claimed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | claimed |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | claimed |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2019-09-05 | — | — | US | claimed |
| EP-3140265-A1 | PROCESS FOR OBTAINING OPTICALLY ACTIVE PIRLINDOLE ENANTIOMERS AND SALTS THEREOF | TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) | 2017-03-15 | — | — | EP | claimed |
| WO-2016138286-A1 | IRGM AND PRECISION AUTOPHAGY CONTROLS FOR ANTIMICROBIAL AND INFLAMMATORY DISEASE STATES AND METHODS OF DETECTION OF AUTOPHAGY | STC.UNM (US) | 2016-09-01 | — | — | WO | claimed |
| US-20160136123-A1 | TREATMENT OF AUTOPHAGY-RELATED DISORDERS | DERETIC VOJO P (US) | 2016-05-19 | — | — | US | claimed |
| WO-2015171003-A1 | PROCESS FOR OBTAINING OPTICALLY ACTIVE PIRLINDOLE ENANTIOMERS AND SALTS THEREOF | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2015-11-12 | — | — | WO | claimed |
| US-20150250808-A1 | TREATMENT OF AUTOPHAGY-BASED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTIC AND SCREENING ASSAYS AND KITS | STC.UNM | 2015-09-10 | — | — | US | claimed |
| WO-2014200705-A1 | TREATMENT OF AUTOPHAGY-RELATED DISORDERS | STC.UNM (US) | 2014-12-18 | — | — | WO | claimed |
| US-20140135296-A1 | METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-15 | — | — | US | claimed |
| WO-2014062621-A1 | TREATMENT OF AUTOPHAGY-BASED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTIC AND SCREENING ASSAYS AND KITS | STC.UNM (US) | 2014-04-24 | — | — | WO | claimed |
| WO-2012154944-A9 | METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | STC.UNM (US) | 2013-02-21 | — | — | WO | claimed |
| WO-2012154944-A2 | METHODS OF TREATING AUTOPHAGY-ASSOCIATED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | STC.UNM (US) | 2012-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BECN1, ATG7, SQSTM1 | HTR1A 1784/4885ADRA2A 2965/4885CHRM1 4294/4885 |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | BECN1, RABGGTB, TFEB | HTR1A 2461/4885ADRA2A 358/4885CHRM1 662/4885 |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, TFEB, ATG7 | HTR1A 2076/4885ADRA2A 264/4885CHRM1 2045/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | HTR1A 1784/4885ADRA2A 2965/4885CHRM1 4294/4885 |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BECN1, ATG7, SQSTM1 | HTR1A 1784/4885ADRA2A 2965/4885CHRM1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.